Navigation Links
Novel enzyme inhibitor paves way for new cancer drug
Date:5/15/2008

(PHILADELPHIA) Combining natural organic atoms with metal complexes, scientists at The Wistar Institute have developed a new type of enzyme inhibitor capable of blocking a biochemical pathway that plays a key role in cancer development.

Based on studies in human melanoma cells, the research paves the way for developing new ways to treat cancer by dampening the overactive enzyme activity that leads to uncontrolled tumor growth.

Details of the study, to be published in the May 16 issue of the journal ACS Chemical Biology, show how small-molecule inhibitors can be designed to target a family of signaling proteins, called phosphatidyl-inositol-3-kinases, or PI3Ks.

The PI3K pathway has been called the most mutated pathway in human cancer, says Ronen Marmorstein, Ph.D., a professor in the Gene Expression and Regulation Program at Wistar and senior author of the study.

PI3Ks are a family of lipid kinases enzymes that transfer a phosphate group to an important signaling molecule in the cell called a lipid. They play a key role in a wide range of cellular functions, including cell growth, proliferation, differentiation, motility, survival and intracellular trafficking. Lipid kinases also drive cell division by modifying fatty acid molecules and directing cells to grow, change shape and move.

Kinases have been the focus of drug development strategies for years, with some protein kinase-inhibiting compounds, such as Gleevec, already being used clinically to inhibit tumor growth. Though pharmaceutical companies have a keen interest in developing similar types of inhibitors for lipid kinases, targeting these enzymes remains a challenge.

The problem is, the drugs often lack specificity, Marmorstein says. Such broad-spectrum compounds, which inhibit many different but related kinases, inevitably cause side effects and are therefore poor drug candidates. For these reasons, none of the PI3K-inhibitors developed to date
'/>"/>

Contact: Abbey J. Porter
aporter@wistar.org
215-898-3943
The Wistar Institute
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
2. Novel mechanisms controlling insulin release and fat deposition discovered
3. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
4. Discovery of a novel mechanism for the development of colon cancer
5. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
6. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
7. Scientists identify novel way to prevent cardiac fibrosis
8. Registry unveils real-world data on novel excel stent
9. Researchers sharpen search for new marine medicines with novel techniques
10. Increased hepcidin expression: A novel oncogenic signalling mechanism
11. Novel discovery by Einstein scientists could lead to much-needed kidney failure treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/8/2009)...long-standing assessment for heart risk may not be...n. 8 (HealthDay News) -- Two studies, from the Uni...acy and value of the long-established Framingham R...scular death. , The Framingham score, based on ...etts community, allows doctors to assess risk on t...
(Date:1/8/2009)...U.S.-Based Alliance of relief organizations offers...INGTON, Jan. 8 Despite ...ivery of food and medical supplies to residents of...ple still lack access to food, clean water and med...id organizations working in the region see this ar...
(Date:1/8/2009)...Senator Dole introduces Senator Daschle at his con...th and Human Services , , , WASHINGTON, Jan. ...ter (BPC) founding board member Senator Tom Daschl...ices Secretary, was introduced by fellow BPC found... hearing today. The hearing was convened by the Se...
(Date:1/8/2009)...ew says it lowered bad cholesterol more effectivel...hDay News) -- After nearly a year of review, U.S. ... the continued use of the controversial cholestero...ug Administration said there was no significant di...nts taking Vytorin and patients taking the drug Zo...
Breaking Medicine News(10 mins):Health News:Studies Challenge Framingham Risk Score 2Health News:Studies Challenge Framingham Risk Score 3Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 2Health News:Temporary Cease Fires Not Enough for Humanitarian Aid Groups Working in Gaza 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 2Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 3Health News:Bipartisan Policy Center Founding Board Members Daschle and Dole Appear on Capitol Hill 4Health News:FDA Backs Cholesterol Drug Vytorin 2
...ach to drink sweet seawater for the second day, th...nst drinking// the polluted water. Scientists cla...he natural phenomenon of dilution. "Dilution is a...long the western coast of India during the southwe...
...be made available in India at the special price of...rer Gilead.// This announcement was made on Sunday...ng deals with three Indian pharma majors - Emcure ...des Arcolab - for the drug. The Indian firms will ...
...ed by the Cleveland Clinic for failing to disclose...ice developed by him.// Yadav is the creator of An...ly used in carotid stenting procedures. Yadav was ... was the chairman of the Clinic's Innovations Foun...
...nistry would seek help from pharmacies in order to...r Public Health Minister// Pinij Charusombat said ...spitals and health workers screen patients might n...macies. "Pharmacists at the drugstores must ask f...
Other Medicine News:Health News:Maharashtra warns against Mahim's 'miracle' water 2Health News:Viread To Retail In India For $1 2Health News:Viread To Retail In India For $1 3Health News:Indo-American Doctor Fired By Cleveland Clinic 2Health News:Indo-American Doctor Fired By Cleveland Clinic 3Health News:Indo-American Doctor Fired By Cleveland Clinic 4
(Date:1/8/2009)...EUVEN, Belgium, January 9 /PRNewswire-FirstCall/ -...died in the Treatment of,Vitreomacular Adhesion i...onext Brussels: THR), a biotechnology company,foc...cular disease and,cancer, announces today that it...croplasmin for the non-surgical treatment of back ...
(Date:1/8/2009)...nts treated at the initial dose in an ongoing Phas...oad decline after three days , , Conference Cal...RNewswire-FirstCall/ -- Anadys Pharmaceuticals, In...the first cohort of an ongoing Phase Ib clinical t...nucleoside polymerase inhibitor. ANA598 was very ...
(Date:1/7/2009)... of Several Products in Development Based On Osteo...imulate Natural BioRegeneration; FDA Filing Antici...., Jan. 7 Osteotech, I...eld of biologic products for regenerative healing,...linical trial for its DuraTech(TM) BioRegeneration...
(Date:1/6/2009)...CK, N.Y., Jan. 6 In recent control...versity of Memphis , scientists found that the pat...s the first and only proven ingredient to increase...increasing blood nitrate/nitrate (NOx) in human su...and enables an increase in blood flow to the skele...
Breaking Medicine Technology:ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 2ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 3ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 2ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 3ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 4ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 5ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients 6Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 2Osteotech Initiates Pivotal Clinical Trial for DuraTech(TM) BioRegeneration Matrix 3US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2Museum Open Around the Clock BODY WORLDS 2 and The Tech Host 40 Hour Marathon 21 9963 1Museum Open Around the Clock BODY WORLDS 2 and The Tech Host 40 Hour Marathon 21 9963 2Military Spouse of the Year 2008 Announced 9961 1Military Spouse of the Year 2008 Announced 9961 2NexCore Group Opens Chicago Office Recruits New Hires 9959 1NexCore Group Opens Chicago Office Recruits New Hires 9959 2Sharps Compliance Corp Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology 2704 1Sharps Compliance Corp Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology 2704 2Sharps Compliance Corp Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology 2704 3Sharps Compliance Corp Announces Purchase of Medical Waste Disposal Facility and Addition of Autoclave Technology 2704 4
...EY, England, April 30, 2007 /PRNewswire-FirstCall/...preading to the,lungs, the brain or the bone which...alised to the breast , Newly published data in the...y Press show that after two years of post-surgical...ive early breast,cancer treated with Femara experi...
... done in collaboration with the Centro de,Investig...University of Navarra, Pamplona, Spain, is being p...tterdam, the Netherlands. , AMSTERDAM, the Netherl...ics BV (AMT), a leader in the field of human gene ...s AMT-020 gene therapy to,treat acute intermittent...
Other Medicine Technology:Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 2Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 3Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 4Newly Published Study Reveals Femara Improves Chances for Harder to,Treat Early Breast Cancer Relapse in Postmenopausal Women 5Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria 2Amsterdam Molecular Therapeutics BV to present preclinical,proof-of-concept data on its gene therapy AMT-020 to treat acute,intermittent porphyria 3
Hook design lifts and separates tissue for efficient dissection. Cautery action facilitates immediate control of bleeders.
The Bair Hugger Model 505 provides safe, quiet and effective warming to patients around the world.
The T5002 has it's temperature set by means of a switch and confirmed by pressing a button. A green LED indicates the unit is on and a flashing amber LED indicates the unit has reached the required t
The SnuggleWarm Convective Warming provides the technology and the tools to effectively enhance the quality of patient care.
Medicine Products: